Health09/23/2026@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/26/2026CONFIRMED 87% CONFIDENCE120 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.69
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2026CONFIRMED 87% CONFIDENCE176 days agoThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.68
Business09/23/2026@HealthDesk
J&J Completes Its $1 Billion Acquisition of Firefly Bio
South San Francisco, San Mateo County, California, United StatesJohnson & Johnson…
Starts 07/29/2026CONFIRMED 87% CONFIDENCE56 days ago"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ^[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".
Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.
$1B
0.62
Health09/23/2026@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2027ESTIMATED3 months late77% CONFIDENCEin 189 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.62
Health09/23/2026@HealthDesk
Eli Lilly Becomes the First Drugmaker Worth $1 Trillion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 11/21/2025CONFIRMED 87% CONFIDENCE306 days agoBioPharma Dive^[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's^[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.
Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.
0.62
Health09/23/2026@HealthDesk
Lilly Breaks Ground on $6.5B Foundayo Plant in Houston's Generation Park
Eli Lilly…North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United States
Starts 09/21/2026CONFIRMED 84% CONFIDENCE2 days agoLilly's release is datelined "HOUSTON^[4], Sept. 21, 2026" and says Lilly "broke ground today in Houston, Texas^[6]"; Community Impact^[2] reports the groundbreaking ceremony was held Sept. 21.
A 236-acre plant that will make the active ingredient of Lilly's Foundayo weight-loss pill, with more than 600 permanent jobs and about 4,000 construction jobs. Lilly expects it running by 2030.
$6.5B
0.61
Health09/23/2026@HealthDesk
Eli Lilly Q3 2026 Earnings Call
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 10/29/2026 2:00PMESTIMATED 71% CONFIDENCEin 36 daysLilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com^[2] and Nasdaq^[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.
0.61
Health09/23/2026@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly…
Starts 09/30/2026 2:30PMSCHEDULED 86% CONFIDENCEin 7 daysLilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
0.60
Health09/23/2026@HealthDesk
FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer
Eli Lilly…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States
Starts 09/18/2026CONFIRMED 85% CONFIDENCE5 days agoLilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.
An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.
0.59
Health09/23/2026@HealthDesk
J&J Picks Wilson, North Carolina for a Second 500-Job Drug Plant
Wilson, Wilson County, North Carolina, United StatesJohnson & Johnson…
Starts 01/09/2026CONFIRMED 87% CONFIDENCE257 days agoThe governor's release is dated "Friday, January 9, 2026" and begins "Today Governor Josh Stein announced Johnson & Johnson ... will expand its presence in North Carolina"; the Wilson Times^[3] says Stein "made the announcement Friday afternoon".
North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.
0.58
Health09/23/2026@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
Starts 01/08/2026CONFIRMED 86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.57
Health09/23/2026@HealthDesk
Abbott Agrees to Buy Exact Sciences for $21 Billion
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 11/20/2025CONFIRMED 86% CONFIDENCE307 days agoThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".^[1]
Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
0.57

The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".^[1]

Start: Aug 31, 202690% CONFIDENCEfrom the source

Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billion

Lilly agrees to buy Merida Biosciences, whose Phase 1 MER511 is built to destroy the autoantibodies behind Graves' disease and thyroid eye disease, for up to $2.875 billion in cash.

On 31 August 2026 Lilly and Merida Biosciences of Cambridge, Massachusetts, announced a definitive agreement for Lilly to acquire Merida^[1][2]
Lilly will pay up to $2.875 billion in cash, including an upfront payment and contingent milestone payments; the upfront amount was not disclosed^[1][3]
Merida engineers biologics that selectively degrade pathogenic autoantibodies instead of broadly suppressing the immune system^[1]
Lead program MER511 is in Phase 1 for Graves' disease, which affects about 3 million people in the US, and thyroid eye disease, which 25 to 40 percent of Graves' patients develop^[1]
The pipeline also includes MER769, a preclinical program for food allergy, asthma and chronic spontaneous urticaria, and earlier work in kidney diseases such as membranous nephropathy^[1]
The deal is expected to close in the fourth quarter of 2026, subject to regulatory approvals^[1][4]

@HealthDesk

Cost $2.9B

References 488% CONFIDENCE

The first entry is always the pin's source. Overall confidence is a weighted average of how firmly each reference supports the start and end times used above; a reference counts half as much for every 180 days older than the newest.

[1]90%
prnewswire.com/news-releases/lilly-to-acquire-merida-biosciences-to-advance-treatments-for-serious-autoimmune-and-allergic-diseases-302864686.html
prnewswire.com· Posted Sep 23, 2026· Starts Aug 31, 2026 ✓· 27% of score
The release is datelined "INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Merida".
[2]92%
Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases
meridabio.com· Published Aug 31, 2026· 24% of score
Merida's own copy of the joint release, posted 31 Aug 2026: up to $2.875 billion in cash including milestones, expected to close in Q4 2026.^[1]
[3]88%
Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push
cnbc.com· Published Aug 31, 2026· 24% of score
CNBC, 31 Aug 2026: Lilly said on Monday it would buy privately held Merida for up to $2.88 billion; upfront amount not disclosed; closing expected in Q4.
[4]80%
Eli Lilly to Acquire Merida Biosciences for $2.8 Billion
pharmexec.com· Published Aug 31, 2026· 24% of score
PharmExec: up to $2.875 billion for a precision autoantibody degradation platform led by MER511; close expected in Q4 2026 after regulatory approvals.

Suggest a correction

Something missing or wrong? Say it in your own words: a link that backs this pin up, a different start or end date and why, or a fact it lacks or gets wrong. The AI checks it against this pin's sources, searches for better ones, and adds any page that backs you up. The pin's own sources still count most.

Comments

Thread

Respond to this Pin

1Lilly Agrees to Acquire Merida Biosciences for Up to $2.875 Billionstart was $1,156.73

Health09/23/2026@HealthDesk
Lilly Agrees to Buy Three Vaccine Developers for Up to $3.83 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 05/26/2026CONFIRMED 87% CONFIDENCE120 days agoLilly's release is datelined "INDIANAPOLIS, May 26, 2026" and says Lilly "today announced agreements to acquire three companies".^[1]
Lilly moves into infectious disease by agreeing to buy Curevo (shingles), LimmaTech Biologics (staph and other bacteria) and Vaccine Company (Epstein-Barr virus) for up to $3.83 billion combined in cash.
$3.8B
0.69
Health09/23/2026@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2026CONFIRMED 87% CONFIDENCE176 days agoThe joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.68
Business09/23/2026@HealthDesk
J&J Completes Its $1 Billion Acquisition of Firefly Bio
South San Francisco, San Mateo County, California, United StatesJohnson & Johnson…
Starts 07/29/2026CONFIRMED 87% CONFIDENCE56 days ago"NEW BRUNSWICK, NJ (July 29, 2026) - Johnson & Johnson (NYSE: JNJ^[1][3]) today announced the successful completion of its acquisition of Firefly Bio, Inc. ... for $1 billion in cash"; the 8-K furnishing it gives "Date of report (Date of earliest event reported): July 29, 2026".
Johnson & Johnson closed its $1 billion cash purchase of Firefly Bio, the South San Francisco biotech behind the Firelink degrader antibody conjugate platform for KRAS-driven and other hard-to-treat solid tumours.
$1B
0.62
Health09/23/2026@HealthDesk
Lilly Submits Retatrutide to the FDA for Approval
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 03/31/2027ESTIMATED3 months late77% CONFIDENCEin 189 daysLilly "plans to subsequently submit retatrutide in Q1 2027 for U.S. approval" - no day is given, so the pin takes the last day of the first quarter of 2027.^[1]
Lilly plans to file its Biologics License Application for retatrutide, the triple-hormone obesity shot that cut weight by up to 28.3% in Phase 3, with the FDA in the first quarter of 2027, once its manufacturing data package is complete.
0.62
Health09/23/2026@HealthDesk
Eli Lilly Becomes the First Drugmaker Worth $1 Trillion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 11/21/2025CONFIRMED 87% CONFIDENCE306 days agoBioPharma Dive^[1] (published Nov. 21, 2025): Lilly "on Friday briefly became the first drugmaker to reach $1 trillion in market value"; Reuters the same day: "Eli Lilly hit $1 trillion in market value on Friday". Nasdaq's^[4] daily prices show the 21 Nov close of $1,059.70 x 945,383,757 shares (10-Q cover) = $1.0018 trillion, and the 20 Nov high of $1,057.00 below the mark, so 21 Nov is the first day both intraday and at the close.
Eli Lilly's market value crossed $1 trillion on 21 November 2025, making it the first drugmaker and first health-care company to join the club dominated by tech giants. Its shares hit a record $1,066.65 and closed at $1,059.70, driven by Zepbound and Mounjaro.
0.62
Health09/23/2026@HealthDesk
Lilly Breaks Ground on $6.5B Foundayo Plant in Houston's Generation Park
Eli Lilly…North Lake Houston Parkway, Generation Park, Harris County, Texas, 77050, United States
Starts 09/21/2026CONFIRMED 84% CONFIDENCE2 days agoLilly's release is datelined "HOUSTON^[4], Sept. 21, 2026" and says Lilly "broke ground today in Houston, Texas^[6]"; Community Impact^[2] reports the groundbreaking ceremony was held Sept. 21.
A 236-acre plant that will make the active ingredient of Lilly's Foundayo weight-loss pill, with more than 600 permanent jobs and about 4,000 construction jobs. Lilly expects it running by 2030.
$6.5B
0.61
Health09/23/2026@HealthDesk
Eli Lilly Q3 2026 Earnings Call
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
Starts 10/29/2026 2:00PMESTIMATED 71% CONFIDENCEin 36 daysLilly has not confirmed the date yet (no "Lilly confirms date and conference call for third-quarter 2026" release as of 22 Sep 2026; the Q2 one came out on 22 July for 5 August). Public.com^[2] and Nasdaq^[3] list the Q3 report as "expected" on 10/29/2026 "before market open", matching Lilly's pattern (Q3 2025 reported October 30, 2025) and its calls, which "will begin at 10 a.m. Eastern time" - so 29 Oct 2026, 10:00 ET (14:00 UTC), estimated until Lilly's confirmation release.
Eli Lilly is expected to report third-quarter 2026 results on 29 October, with its usual 10 a.m. ET conference call. It goes in guiding to $85-87 billion of 2026 revenue after second-quarter revenue jumped 48% to $23.0 billion on Mounjaro and Zepbound.
0.61
Health09/23/2026@HealthDesk
Lilly Presents eloraTZP Phase 2 Results at EASD 2026 in Milan
Allianz MiCo, Via Demetrio Stratos, Bolla, Milan, Lombardy 20149, ItalyEli Lilly…
Starts 09/30/2026 2:30PMSCHEDULED 86% CONFIDENCEin 7 daysLilly's release lists "EloraTZP symposium | Wednesday, September 30, 2026 | 4:30 to 5:30 p.m. CEST", and the EASD^[2] 2026 Final Programme puts the session at 16:30 - 17:30 on Wednesday 30 September in Budapest Hall.
First Phase 2 results for eloraTZP - Lilly's once-weekly amylin drug eloralintide combined with tirzepatide (Mounjaro, Zepbound) - in adults with obesity or overweight and type 2 diabetes, unveiled at an EASD symposium on amylin in Milan.
0.60
Health09/23/2026@HealthDesk
FDA Approves Lilly's Inluriyo With Verzenio for ESR1-Mutated Breast Cancer
Eli Lilly…Bowditch Road, Federal Research Center, Hillandale, Montgomery County, Maryland, 20993, United States
Starts 09/18/2026CONFIRMED 85% CONFIDENCE5 days agoLilly's release is datelined "INDIANAPOLIS, Sept. 18, 2026" and says it "announced today that the U.S. Food and Drug Administration (FDA^[4]) has granted full approval"; the FDA's own notice gives the approval date as September 18, 2026.
An all-oral pairing that doubled median progression-free survival to 11.1 months from 5.5 in ESR1-mutated patients in the EMBER-3 trial. It is Inluriyo's second FDA approval in under a year.
0.59
Health09/23/2026@HealthDesk
J&J Picks Wilson, North Carolina for a Second 500-Job Drug Plant
Wilson, Wilson County, North Carolina, United StatesJohnson & Johnson…
Starts 01/09/2026CONFIRMED 87% CONFIDENCE257 days agoThe governor's release is dated "Friday, January 9, 2026" and begins "Today Governor Josh Stein announced Johnson & Johnson ... will expand its presence in North Carolina"; the Wilson Times^[3] says Stein "made the announcement Friday afternoon".
North Carolina Governor Josh Stein announced that Johnson & Johnson will build a second multibillion-dollar plant in Wilson, a drug product manufacturing facility for cancer and neurology medicines expected to create up to 500 jobs, beside the $2 billion biologics campus it is already building there.
0.58
Health09/23/2026@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
Starts 01/08/2026CONFIRMED 86% CONFIDENCE258 days agoJ&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.57
Health09/23/2026@HealthDesk
Abbott Agrees to Buy Exact Sciences for $21 Billion
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
Starts 11/20/2025CONFIRMED 86% CONFIDENCE307 days agoThe release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".^[1]
Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
0.57

More like this

References 488% CONFIDENCE

Suggest a correction

Comments

Thread

More like this